• Poster

First-Line Treatment With Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for Patients with ErbB2+ (HER2+) Metastatic Breast Cancer: Quality of Life Analyses Using Repeated Measures and Pattern Mixture Models

Citation

Sherrill, B., Wu, Y., Amonkar, M., Arbushites, M., & Di Leo, A. (2009, June). First-Line Treatment With Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for Patients with ErbB2+ (HER2+) Metastatic Breast Cancer: Quality of Life Analyses Using Repeated Measures and Pattern Mixture Models. Presented at 2009 ASCO Annual Meeting, .

Abstract